Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Rusky, :) they can broker having a foot as an investor in the SAR camp there is no conflict, in fact if anything I like that they have skin in the game. They are not acting or claiming to be an independent, as in that instance I would of course concur.
As a general observation my position on PH is that they are exactly what we need, they are subject matter experts with a great track record....I am just expecting that as we are on the verge of greatness, I want to see great things.... at some point I do need to remind myself of the possibility of a NDA clause in any discussions that may be ongoing.
GLA
You simply cant rush the whole research and development, particularly the clinical trial stages , however one could think that there is procrastination on the part of PH in their appointed position as corporate broker. The perception seems from the outside to be very passive and certainly there isn't any obvious evidence coming forward that Peel are doing anything spectacular on the book making front.
The role of the corporate broker includes best finding business's with a big appetite for a little aim company with some real game changers(I believe this may be already in place and why PH are part of the team). We should also see PH waving a big promo flag, with more wide-ranging duties to include the publication of research on the company, dealing in the companies shares on behalf of the hnwi's and shareholders, even raising finance, but I'am not seeing the visibility of this. Having two brokers? that is normal each with different areas of expertise but if PH are dealing with either an M&A (even under a non-disclosure agreement) they are not going out of their way to creating a business net worth in the SP. Raising awareness for any private investors is paramount to a brokers job, so where is it, where are they creating liquidity and encouraging even subliminally regular share trades/volume. I am not doubting the science, in fact it is interesting me less and less the more I read, probably because that multiple SAR offering all makes this a red-hot favorite at New-market, but I am feeling frustrated that PH are not doing anything visibly to making us look like an absolute, unquestionably strong best turned out ride. Modesty is not very becoming on AIM, some times when you are good you need to tell people just how good you are especially as PH are one of our appointed corporate brokers. With some really amazing stuff in the pipeline including the patented elements the SP is giving anyone interested in buying a staggeringly great value opportunity for their share portfolio.
On the premis SAR are not a pharma manufacturer on in their present form they never will be. Agile then is one of a number of ways to fund R&D. Depending on what is (may) currently being discussed, a commodity sale of a product that A another manufactures and takes to market or a full M&A , agile, or just the mention of agile shows that the business has options. Those funding options, agile being one strengthens any negotiations in regard to not being wholly dependent on others. I believe it adds to the SAR board choices. I am less interested in the medical science an nor do I have any sentiment in regard to keeping control.... this is pure business and PH are right in the eye of a perfect storm tabling the value of all of the business offering combined or part of a single offering resulting from the stage development particularly once at clinical trials. It's early in the remit of PH but they will be developing a strategic mission, goal, objective with the Board of how SAR move forward. We are just not privy to this as yet, neither is the SP reflecting this. I quite like the idea of milking this cow multiple times, some steady incremental growth of their net worth rather than a one time barbecue.... but if a one time barbeque gets Th2 a Yacht and an opportunity to smoke his beef :) (?) that works well for me. GLA
Absolutely convinced that Peel Hunt Have now started the process of readying the business for a formal merger or acquisition. The director share sale option was time barred and is not something that either have asked to do, it was not a personal choice but rather part of PH reducing any complications of open liabilities inside a formal M&A. It was invoked on them by PH and the Board. What does surprise me is how quickly these are going to be released for sale, as I would have expected PH to delay this while they market the SP value up. So what’s the urgency, it’s not a fire sale, we’ve just seen the most confident investor presentation in the history of SAR, the envy of any R&D company who is looking for a merger to future proof their business or more likely large pharmaceutical. It’s the timeline of events that to me points in one direction of PH being brought in to commence brokering the due diligence prior to a formal sale. So the urgency to clear up any new owners Director liability or complications makes sense as does the quick release to market of these shares which now makes way, should the timing be appropriate for an imminent announcement of an external interest. They well be on the verge of being bound to silence by this formal sale brokering process commencing so as I said news in this scenario is more than likely to be imminent. GLA
Our sector teams provide integrated Financial Advisory and Capital Markets Services as well as sector coverage. Each team is exclusively focused on their chosen area. It means they are better informed and able to give the best strategic advice.
Really interesting, you don’t employ big guns like Peel on a whim and their fees will be top end of the broker market. Aim regulation expertise and taking a concept into implementation of large strategic and financial process.....take over panel leaders of long term franchise with large corporate... it’s pleasing to see they are employing a company of this standing to represent their/our interests....
I was just reading Badstermans post on Sunday... referencing Sareum's Dr Michael Owen (Non Exec Director) co-founded Kymab. Their monoclonal antibody was purchased by Sanofi for 1.1 BILLION plus 350,000 milestone payments.
With a multitude of game changers in development we only need one of these to come home and the SP is stepping up beyond any of my original expectations.
An equivalent of a LSE slapped wrist, a few individuals been reminded that they need to be more tolerant when communicating with differing views. They made for a good read late last night... it got a bit World Heavy Weight Boxing ... LOL
SR I wouldn’t engage in encouraging his conspiracies, a real flat earth member of society that can’t see how his contribution to standing by the rest of mankind to have the vaccine is so important to saving the lives of others. We all have a responsibility to do our part.
BINGO its so good to read this, it is what so many posts are missing, quote RMM3383 "once we have a successful drug (or what looks like a successful drug) then the science no longer holds centre stage but the commercial negotiations become paramount."
For me this is exactly where we are, all of the continuous posts about the science however informative are not at the business end of this next deal stage... SAR have entered the stage of the boys who will negotiate the future of this holding which if it is Dr Parker and his commercial and legals team I have maximum confidence in them.
As for the pending year end results, the nature of this business requires expenditure on R&D so they will show less in the bank and expenditure with little revenue...so don't be dismayed by this, its a good thing providing they are spending it in the right areas that will attract the buyers... the strategic model requires expenditure to licence at pre-clinical or early clinical stages at which point..... we are back to the point of the negotiations stage being paramount in realizing the true value of whichever the commodity is that SAR are selectively taking to the market.
SAR are full-filling their strategic plan and focusing on their core business activities..... the question that I am sure will be answered, governed by any disclosure restrictions, at the Investor Presentation is the future projections and where and what licensed commodity will they be brokering with the big pharmas.
This is indeed great news, only a fool would make a company investor presentation in to a negative.
A strategic presentation of what has been achieved to date, our financial standing , the functional strategy to implement the future of SAR and the size and direction of the carrots in regard to developments.
Very pleased and this all forms part of the busy 2 months....excellent soap box communication opportunity.
For me its north of £1, but even then I think the savvy investors will look to see what SAR still have in the bag. If there isn't a TO and we still have on going R&D or new patents going in to advanced stages and there is demand/keen interest then I will continue to hold and enjoy the sport of this holding. Red Adair would have a job capping this.
No problem with that source. Similar situation.... Bags packed, Pre-Flight Checks on going and waiting for the take-off.
Hopefully its going to be a long long time till this Rocket Man touch's down again.
Thanks
Dqhohang not sure where you've popped up from but thank you for the exceptional correspondence from you. There is nothing held back, just a really transparent vision of how you see the future.
Greatly appreciated and would be pleased to continue to see similar posts from you as they would be well received.
Looks like Sar will be knocking the ball out of the park very shortly. I would welcome an update on activities from the business even if it’s not the big RNS, that will come though, most likely in a multiple flurry. Get all their ducks in a row and when able disclose the news. Happy for a proportionate response from the market today, we don’t need to rush, but I am of a mind that there is some significant activity ahead of us.. GLA
As previous posts, I envisaged that Sareum at both the cutting coalface of R&D/Clinical Trials, doing the day job, keeping investors feeling like they are valued and negotiating the terms and conditions of their route to market would be busy throughout whole of September and October.
I maintain that the most significant opportunity and route to market for Sar is GSK of which with the busy Sept and October out of the way I think we will get some firmed up news early Nonmember. There remains several other routes to market for this business all of which would give the investors a relevant stakeholder return.
The business is cash rich, it doesn't need any money to keep the lights on and some of the ridiculous talk on inflation recently effecting an R&D not reliant on any volatile commodities is, to anyone with an ounce of business acumen just nonsense. My critique of the business remains unchanged in respect to how poorly it communicates outside of the business, it needs a big flag and a soap box even just to give a no news bulletin of what is occurring. Some things remain confidential under NDA's that understandable but a few snippets on their website, Twitter, Linkedin, Podcasts or med journals to keep them visible is what the spin doctor or marketing guru's need to prescribe. Anyway, we need them to continue with their heads down and once they've done so there is an inordinate amount of good news sat there that make this the most exciting prospect of all my holdings. Well done for those who remain active, serious commitment and plaudits for holding of the wombles they are a threat to mankind and acceptable behaviour/good conduct, but I will be hibernating for a bit longer with expectations of a torrent of strong news.
I don’t think it’s a bad synopsis, it makes some pretty inconclusive statements and whilst sitting on the fence does make reference to an opportunity to break back to the previous trajectory. If anything I am pleased to see someone talking about us. We remain, in many quarters a best kept secret. GLA
Hope everyone isn’t going to continue with 4.4m share Sell subject thread today…. It’s like a rain cloud… in monetary terms it’s small… You lot need some rose tinted glasses ;) This remains a really exciting opportunity for anyone’s investment portfolio.
What does nark me about Sar is there inept ability to communicate…no big RNS needed but a few tweets , a podcast or simple updates on their website is what all businesses are doing now… it attracts clients, investors, retains staff, attracts resource but nothing. Where as Stephen Parker can’t get enough positive but general tweets in about his cannabis farming.
Actually final statement (Full Accounts) likely after AGM (Dec) following on from the Confirmation Trading Statement in August…. investor presentation expectations and an AGM will be a driver for positive news. SAR would appear to be sat on an extensive amount of pending investor updates therefore exciting period ahead for this holding.